ericsphotography / iStockphoto.com
7 January 2019Big Pharma
India removes cap from patented rare disease drugs
India’s Department of Pharmaceuticals (DoP) has removed a price cap from a range of essential patented drugs used in the treatment of rare diseases.
Already registered?
Login to your account
If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk
Asia-Pacific
21 November 2018 The Delhi High Court has ruled against a company for its ‘near identical’ imitation of pharmaceutical company Sanofi’s name and trademarks.
Asia
12 February 2019 The lobby group for India’s pharma industry has asked the US Trade Representative office to remove India from its Priority Watch List of places that have weak enforcement of intellectual property laws.
Editor's picks
Editor's picks
Asia-Pacific
21 November 2018 The Delhi High Court has ruled against a company for its ‘near identical’ imitation of pharmaceutical company Sanofi’s name and trademarks.
Asia
12 February 2019 The lobby group for India’s pharma industry has asked the US Trade Representative office to remove India from its Priority Watch List of places that have weak enforcement of intellectual property laws.
Asia-Pacific
21 November 2018 The Delhi High Court has ruled against a company for its ‘near identical’ imitation of pharmaceutical company Sanofi’s name and trademarks.
Asia
12 February 2019 The lobby group for India’s pharma industry has asked the US Trade Representative office to remove India from its Priority Watch List of places that have weak enforcement of intellectual property laws.